Entering text into the input field will update the search result below

Longeveron stock jumps 29% on FDA orphan designation to Lomecel-B

Dec. 03, 2021 6:40 AM ETLongeveron Inc. (LGVN)By: SA News Team

Success business chart with green arrow up and USA dollars background. Profit and money. Financial and business graph. Stock market growth 3d illustration.

JuSun/iStock via Getty Images

  • Longeveron (NASDAQ:LGVN) soars 29.1% premarket after FDA granted orphan designation to Lomecel-B, its allogeneic bone marrow-derived mesenchymal stromal cells, or MSCs, as a treatment of Hypoplastic Left Heart Syndrome.
  • Among the benefits of Orphan Drug status in

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.